Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.
临床试验结果为使用信号缺陷型 HIV 融合抑制剂保护双重 HIV 特异性 T 细胞提供了理论依据。
期刊:Molecular Therapy
影响因子:12
doi:10.1016/j.ymthe.2026.01.006
Tebas Pablo, Jadlowsky Julie K, Zhou Yuqi, Pampena M Betina, Leslie George J, Liu Nan, Srivatsa Sriram, Maldini Colby R, Wang Jingxin, Tsang Chungdhak Jaming, Mohamed Ola, Romano Josephine, Haggarty Beth, Plesa Gabriela, Gaymon Avery L, Brennan Andrea L, Veloso Elizabeth, Levine Bruce L, Putt Mary E, Kulikovskaya Irina, Gonzalez Vanessa, Fraietta Joseph A, Betts Michael R, Hoxie James A, Riley James L
